Scancell raises £30mln to advance growing pipeline of cancer immunotherapies and COVID-19 vaccine
An additional £3mln open offer will provide existing investors with the chance to acquire new stock in the business
Company
Scancell Holdings PLC
LON:SCLP
Scancell is a clinical stage biotech company developing immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. With deep roots in cancer immunology and translational research, the company aims to translate its innovation and creativity to address the need for fast, potent and accessible therapies that are easy to administer in hard-to-treat cancers.
329 stories · page 7 of 17
Archive
Proactive news headlines: Scancell, OptiBiotix Health, One Media IP, Brunner Investment Trust...
A glance at some of the day's highlights from the Proactive Investors newswire
Scancell Holdings takes crucial step in Covid vaccine preparations by teaming up with Cobra Biologics
The agreement covers the good manufacturing pracatice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2
Scancell Holdings consortium gets government backing for Covid trial
The funding for a team, led by chief scientific officer, Prof Lindy Durrant, is coming from Innovate UK
Scancell completes oversubscribed fundraising to support coronavirus vaccine development
The cash will also be used to support the company's Modi-1 and SCIBI clinical trials
Scancell publishes new research highlighting potential of Modi-1 in hard-to-treat cancers
Scancell is preparing a regulatory submission for a phase I/II clinical study in the UK in the first half of 2021.
Scancell Holdings has AvidiMab paper published in prestigious cancer journal
The paper describes how AvidiMab modifications improve an antibody’s potential therapeutic properties
Small cap movers: Coronavirus crisis shines a light on small-cap pharma
A look back at some of the more interesting stories from London's junior market this week
Archive
Proactive news snapshot: Scancell, SDX Energy, Tekcapital, Genedrive, Inspiration Healthcare …
A glance at some of the day's highlights from the Proactive Investors newswire
Scancell soars as it begins research into coronavirus vaccine
The company is anticipating a phase 1 clinical trial in the first quarter of 2021
Scancell receives US regulatory green light
The US Food & Drug Administration has granted investigational new drug status to the firm's lead drug, SCIB1
Scancell Holdings looks to increase the number of UK phase II trial sites for lead drug
The update was provided alongside the firm’s interim results, which charted a busy period for the immunotherapies specialist, one in which it brought on board a new major shareholder, the Vulpes Life Science Fund
Scancell surges as it inks third collaboration deal for AvidiMab technology
The US firm will conduct preclinical studies to evaluate whether antibodies developed by Scancell's AvidiMab platform can treat cancer
Scancell signs second AvidiMab collaboration, this time in China
This is the company's second research agreement, following the first in September
Scancell Holdings close to securing further patent protection over the IP underpinning its Moditope platform
"The utility of the Moditope technology is increasingly being recognised as a novel and important immuno-therapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation o
Scancell Holdings appoints new independent director
Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn who stands down from end October
Scancell hails first antibody collaboration deal
The company is teaming up with an unnamed "major player" in the world of antibodies
Scancell Holdings lays groundwork for pivotal year
A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D
Scancell to begin UK arm of phase II skin cancer trial ‘immediately’
Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date
Investments and investor services
Renalytix AI gets payment code for its lead product
A look at the day's major movers, including Upland Resources, Mosman, Malvern International, Lekoil, AA, Prospex, Frontier Smart and Future